Addus HomeCare closed 2025 with a strong fourth quarter, growing revenue 25.6% year-over-year to $373.1 million, adjusted EPS 28.3% to $1.77 and adjusted EBITDA 33.3% to $50.3 million (a 13.6% margin); full-year revenue reached approximately $1.4 billion with adjusted EPS of $6.23 and adjusted EBITDA of $180 million. Personal Care Services (76.5% of revenue) grew 6.3% same-store on a 2.4% rise in billable hours, while Hospice grew 16% same-store with average daily census up 11.9% to 3,885, aided by the October Medicare rate increase. Home Health remained the soft spot, with same-store revenue down 7.5%, prompting new market-president and sales leadership hires to target a return to growth in the second half of 2026 - helped by a CY2026 final rule far more favorable than the proposed 6.4% cut. Adjusted G&A improved to 19.1% of revenue, though Q4 operating cash flow was a lighter $18.8 million as the Illinois Department on Aging DSO spiked to 54.7 days; the company still ended the year with $81.6 million of cash, bank debt of $124.3 million and net leverage under 1x. Management secured a Texas 9.9% and Illinois 3.9% personal care increase, flagged a likely 4%-5% New Mexico increase pending the governor's signature, expressed confidence the 80/20 Medicaid Access Rule will be eliminated, and pointed to a building acquisition pipeline that could include larger personal care assets in 2026.
Thank you. Good morning, and welcome to the Addus HomeCare Corporation Fourth Quarter and 2025 earnings conference call. Today's call is being recorded. To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure, calculated according to GAAP, by going to the company's website and reviewing yesterday's news release. This conference call may also contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Addus expected quarterly and annual financial performance for 2026 or beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward-looking statements.
Without limiting the foregoing, discussions of forecasts, estimates, targets, plans, beliefs, expectations, and the like are intended to identify forward-looking statements. You are hereby cautioned that these statements may be affected by important factors, among others, set forth in Addus filings with the Securities and Exchange Commission and in its fourth quarter 2025 news release. Consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. I would now like to turn the call over to the company's chairman and chief executive officer, Mr. Dirk Allison. Please go ahead, sir.
Thank you, Dru. Good morning, and welcome to our 2025 fourth quarter earnings call. With me today are Brian Poff, our Chief Financial Officer, and Heather Dixon, our President and Chief Operating Officer. As we do on each of our quarterly earnings call, I'll begin with a few overall comments, and then Brian will discuss the fourth quarter results in more detail. Following our comments, the three of us would be happy to respond to any questions. As we announced yesterday afternoon, our total revenue for the fourth quarter of 2025 was $373.1 million, an increase of 25.6% as compared to $297.1 million for the fourth quarter of 2024.
This revenue growth resulted in adjusted earnings per share of $1.77, as compared to adjusted earnings per share for the fourth quarter of 2024 of $1.38, an increase of 28.3%. Our adjusted EBITDA was $50.3 million, compared to $37.8 million for the fourth quarter of 2024, an increase of 33.3%. For 2025, our total revenue was approximately $1.4 billion, which is an increase of 23.2% as compared to approximately $1.1 billion for 2024. This revenue growth resulted in adjusted earnings per share of $6.23, as compared to adjusted earnings per share for 2024 of $5.26, an increase of 18.4%.
Our adjusted EBITDA for 2025 was $180 million, as compared to $140.3 million for 2024, an increase of 28.3%. For the fourth quarter of 2025, cash flow from operations was $18.8 million as of December 31, 2025, and we had cash on hand of approximately $81.6 million. We ended the fourth quarter with bank debt of $124.3 million, leaving us with net leverage of under 1x adjusted EBITDA, allowing us the flexibility to continue to evaluate and pursue acquisition opportunities that meet our ongoing strategy of creating geographic density and scale while focusing on the full continuum of Home Care.
As we mentioned on our last earnings call, both the states of Texas and Illinois have recently increased our rates in Personal Care Services. The Texas rate increase was effective on September 1st, 2025. The Illinois rate increase went into effect on January 1st, 2026, and will be reflected in our 2026 first quarter results. While there are potential future changes to Medicaid due to OBBBA, we believe that our value proposition for Personal Care Services is recognized by the states where we operate. We believe that we can be a cost-effective partner to both our states and managed Medicaid payers as they look for potential savings, as home-based care is substantially less costly than facility-based care. We will continue our legislative efforts in states where we operate to emphasize the benefits generated by their continuing support of these services.
As we've stated before, we continue to believe that the 80/20 provision of the Medicaid Access Rule will be eliminated in the near future. While implementation is still several years away and has no current impact on our business or financial performance, we believe this outcome would be a significant and encouraging development for the industry and our company. During the fourth quarter of 2025, we continued to experience positive hiring trends in our personal care segment. While the holidays typically slow our hiring, we are still able to achieve 101 hires per business day during the fourth quarter. As we began 2026, our hiring numbers for the first two weeks of January increased to 107 hires per business day.
We saw a slight slowdown in hiring due to severe weather in certain of our markets over the last couple of weeks of January. We have seen hiring rebound in February as the winter storms have dissipated. As we have mentioned, the last few quarters, our clinical hiring remains consistent and has been mostly stable outside of a few more challenging urban markets. Let me discuss our same-store revenue growth for the fourth quarter of 2025. As a reminder, these calculations exclude our Gentiva acquisition, as they were not part of our business for the entire fourth quarter in 2024. For our personal care segment, our same-store revenue growth was 6.3% compared to the fourth quarter of 2024.
During the fourth quarter of 2025, we saw personal care same-store hours increase by 2.4% compared to the same period in 2024, while our percentage of authorized hours served in the fourth quarter remained consistent with what we experienced in the third quarter of 2025. On a sequential basis, personal care same-store billable census was down slightly, although we continue to see census growth in the majority of our key states. This should positively impact our billable census during 2026. During the fourth quarter, our personal care same-store growth was more evenly divided between volume and rate, as we have been expecting. Turning to our clinical operations, our Hospice same-store revenue increased 16% compared to the fourth quarter of 2024.
Our average daily census increased to 3,885 for the fourth quarter, up from 3,472 for the same period last year, an increase of 11.9%. For the fourth quarter of 2025, our Hospice median length of stay, inclusive of our Illinois JourneyCare operation, was 25 days, as compared to 22 days for the third quarter, again, including JourneyCare. We are very pleased by the continuing growth in our Hospice segment over the past several quarters as a result of operational improvements.
While our Home Health same-store revenue decreased 7.54% when compared to the same quarter of 2024, it is important to point out that over 25% of our Hospice admissions in New Mexico and Tennessee are currently coming from our Addus HomeCare operations, which overlap in these two markets. We are pleased to see more patients receiving the benefit of the full continuum of post-acute care and anticipate seeing similar clinical collaboration and support develop in Illinois, where we also have both Home Health and Hospice operations. Our development team continues to focus on both clinical and non-clinical acquisition opportunities, which would increase both density and geographic coverage. We will continue our disciplined approach to identify strategic personal care service transactions, as well as to evaluate smaller clinical transactions.
That said, while there is more optimism around Home Health care due to the final health rule for 2026 being more favorable than was originally proposed, questions remain about potential future in rate increases and the uncertainty of the retrospective payment adjustments. Before I turn the call over to Brian, I want to thank the Addus team for the care they are providing our elderly and disabled consumers and patients. We all have come to understand that the overwhelming majority of this population prefers to receive care at home, which remains one of the safest and most cost-effective places to receive this care.
We believe the heightened awareness of the value of home-based care is favorable for our industry and will continue to be a growth opportunity for our company. We understand and appreciate that our operations and growth are dependent on both our dedicated caregivers and other employees who work so incredibly hard providing outstanding care and support to our clients, patients, and their families. With that, let me turn the call over to Brian.
Thank you, Dirk, and good morning to everyone. The fourth quarter of 2025 marked a strong finish to another year of growth and progress for Addus. Our results for the year reflect the continuing execution of our strategy, which allows us to both deliver consistent organic growth and realize the benefit of our recent acquisitions. Our results were highlighted by 25.6% top-line revenue growth and a 33.3% increase in adjusted EBITDA compared with the fourth quarter last year. Our Personal Care Services segment was the primary driver of our business, with a solid 6.3% organic revenue growth rate over the same period last year, above our normal expected range of 3%-5%.
Our results were supported by stable hiring trends and favorable rate support for Personal Care Services in some of our larger markets, including a 9.9% rate increase in Texas that was effective September 1st, 2025. The State of Illinois, which represents our largest personal care market, had previously approved a 3.9% increase that became effective January 1st, 2026, and is expected to add approximately $17.5 million in annualized revenue for Addus, with margins consistent in the low 20% range. Our personal care results include the Gentiva personal care operations, our largest acquisition to date, which we completed on December 2nd, 2024.
The results also include Great Lakes Home Care, acquired on March 1st, 2025, Helping Hands Home Care Service, acquired on August 1st, 2025, and the personal care operations of Del Cielo Home Care, acquired on October 1st, 2025. During the fourth quarter, we had a benefit of approximately $1.9 million related to accounts receivable settlements from our previously divested New York operations. This was reflected as a positive revenue adjustment and has been excluded from our adjusted results and same-store metrics. We continued to see solid performance in our Hospice business, which accounted for 18.9% of our revenue for the fourth quarter. The operational improvements we have made over the past year resulted in solid 16% year-over-year organic revenue growth, supported by increases in admissions, average daily census, and revenue per patient day.
We also benefited from an approximate 3.1% increase in the 2026 Medicare Hospice reimbursement rate that became effective October 1st, 2025. Our Home Health services represent our smallest segment, accounting for 4.6% of fourth quarter revenue. We continue to look for ways to support and expand this service line, including via acquisitions, as we believe there are synergy opportunities associated with offering all three levels of home-based care in the markets we serve. In addition to the consistent organic growth achieved in 2025, we have also benefited from our recent acquisitions. Last year was the first full year to include the acquired personal care operations of Gentiva, which we completed in December 2024, adding approximately $280 million in annualized revenues and significantly expanding our market coverage.
In 2025, we completed three other acquisitions: the operations of Great Lakes Home Care in Michigan on March 1st, Helping Hands Home Care Service in Pennsylvania on August 1st, and the personal care operations of Del Cielo Home Care Services in Texas on October 1st. We will continue to source and evaluate additional similar acquisitions that are strategic for Addus. Our primary focus will be on markets where we can leverage our strong personal care network, as we believe having geographic coverage and density provides us with a competitive advantage. We will also look for opportunities to add clinical services in pursuit of our goal of offering the full continuum of home-based care in the markets we serve. With our size and expanding scale and the support of a strong balance sheet, we are well positioned to execute our acquisition strategy.
As Dirk noted, total net service revenues for the fourth quarter were $373.1 million, or $371.2 million, excluding the impact of the New York accounts receivable settlements. The revenue breakdown, excluding the New York impact, is as follows: Personal care revenues were $284.1 million, or 76.5% of revenue. Hospice care revenues were $70 million, or 18.9% of revenue, and Home Health revenues were $17.1 million, or 4.6% of revenue.
Sequentially, from the fourth quarter of 2025, revenue of $371.2 million, excluding the New York impact, we expect the first quarter of 2026 to benefit from the Illinois rate increase, offset by two fewer business days in personal care and some seasonal impact from the winter storms we experienced in certain markets. Other financial results for the fourth quarter of 2025 include the following: excluding the impact of the New York accounts receivable settlements, our gross margin percentage was 32.8%, compared with 33.4% for the fourth quarter of 2024, primarily driven by a higher mix of Personal Care Services from the Gentiva acquisition. As expected, we saw a positive impact sequentially from the third quarter of 2025 from the Medicare Hospice rate increase and lower unemployment taxes.
Looking ahead to the first quarter of 2026, we expect normal seasonality in our gross margin %, with a negative impact from our annual merit increases and the normal annual reset of payroll taxes. Cumulatively, we expect these items to contribute a decline sequentially in gross margin % of approximately 120 basis points compared to the fourth quarter of 2025. G&A expense was 20.7% of revenue, compared with 24% of revenue for the fourth quarter a year ago, primarily due to lower acquisition expenses as well as incremental leverage from our higher revenue base. Adjusted G&A expense for the fourth quarter was 19.1%, a decrease from 20.5% in the comparable prior year quarter, and lower sequentially from 19.8% in the third quarter of 2025.
Company's adjusted EBITDA increased 33.3% to $50.3 million, compared with $37.8 million a year ago. Adjusted EBITDA margin was 13.6%, compared with 12.9% for the fourth quarter of 2024, and higher sequentially from 12.5% in the third quarter of 2025. Adjusted net income per diluted share was $1.77, compared with $1.38 for the fourth quarter of 2024.
The adjusted per share results for the fourth quarter of 2025 exclude the following: the impact of New York accounts receivable settlements of $0.07, acquisition expenses of $0.05, and non-cash stock-based compensation expense of $0.18. The adjusted per share results for the fourth quarter of 2024 exclude the following: Gain on sale of assets related to the New York divestiture of $0.15, impact of lease impairment of $0.20, impact of the retroactive New York rate increase of $0.14, acquisition expenses of $0.29, and non-cash stock-based compensation expense of $0.11. Our tax rate for the fourth quarter of 2025 was 25.8% within our expected range. For calendar 2026, we expect our tax rate to remain in the mid-20% range.
DSO was 38.2 days at the end of the fourth quarter of 2025, compared with 35 days at the end of the third quarter of 2025. We have continued to experience consistent cash collections from the majority of our payers. Our DSO for the Illinois Department on Aging for the fourth quarter increased to 54.7 days, compared with 32.5 days at the end of the third quarter of 2025, as we saw some expected timing differences in payment cycles. In the first quarter of 2026, we have seen our DSO in Illinois return to a level more consistent with what we experienced for the majority of 2025.
Our net cash flow from operations was $18.8 million for the fourth quarter of 2025, and $111.5 million for 2025, with some negative working capital impact in the fourth quarter, primarily from the increase in Illinois DSO. During the fourth quarter of 2025, we did receive approximately $7.2 million in phase 3 ARPA funding from New Mexico, with an additional $5.8 million received from the state in the first quarter of 2026, for a total of $13 million. We anticipate these to be the last scheduled disbursements from New Mexico, which will leave us with approximately $17.5 million in funds remaining to be utilized.